This research aims to evaluate the survival outcomes of retifanlimab combined with carboplatin and paclitaxel in patients with first-line advanced squamous anal cancer.
Phase 3 trial design
Participants received retifanlimab plus carboplatin and paclitaxel
Study conducted globally, including Australia.
The combination therapy improved overall survival rates in the treatment group compared to historical controls.
Exact survival metrics and statistical significance were not provided in the abstract.
Abstract
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer POD1UM-303/InterAACT-2Global (Australia,